Quin is pioneering a new era of direct-to-consumer Virtual Care 2.0 for diabetes that doesn’t rely on human healthcare professionals. Unlike existing diabetes platforms, which add a digital veneer to already ineffective analogue healthcare models, Quin goes deep into the 24x7 needs of the individual living with the condition. Their groundbreaking personalization model empowers people to better manage on their own, when they’re away from their doctors and living their day-to-day life — where 99.9% of diabetes care actually happens. The first Quin app is a novel digital therapeutic for personalized independent self-management of type 1 diabetes. It regularly ranks in the top #1-3 most-downloaded diabetes apps in the App Store in the UK and Ireland. 96% of Quin users experience better health outcomes or wellbeing, or both. Early data shows a massive opportunity to improve time-in-range (a critical healthcare metric) by 10-20% for those starting at less than 70%.

Dario recognizes that much of what creates worsening in chronic disease is behavior--the choices people make directly influence short and long-term outcomes. In order to truly improve outcomes in chronic disease, behavior change should be the path of least resistance. Dario empowers members with clinically proven, easy to use tools and approaches that help them recognize, address and change the overlapping behaviors that cause worsening of their conditions. The program includes: Program Focus: Diabetes, hypertension, pre-diabetes, obesity and behavioral conditions impacting chronic disease such as stress, anxiety and loneliness. Dario Devices: Easy to use digital devices that interface directly and simply with the member’s existing smart phone (IOS and Android), and include blood glucose, blood pressure monitors and weight scale MyDario™ App: available to download from the App Store Clinical indications upon data capture (e.g., weight increase/decrease, glucose in-range, blood pressure high/low) Contextual logging of the specific event and all its related data (e.g., location, carbs, food pictures, medication and insulin intake, physical activity, mood, time, notes) Real-time AI driven digital feedback and intervention based on positive/negative trends, cause/effect alerts, and lapse in clinical data capture over time In-app alerts with calls to action and positive messaging Automatic log-book: Records all user activities and presents clear trend graphs over time Dario Journey Engine: Behavior is a predominant driver of chronic disease. DarioHealth's unique approach to changing behavior is powered by its AI-driven Journey Engine. Applying tens of billions of data points from over 65,000 Dario users in combination with an individual's own data and preferences, the platform makes effective behavior change the path of least resistance through a personalized user experience. DarioEngage: A flexible, open platform that enables real-time coaching and support and direct viewing of digital inputs from devices and member. Coaching can be delivered by a Dario coach or a Client/Third Party coach. Dario Engage provides immediate data on member measurements and inputs, allowing for a rich coaching experience and data driven decision making.

DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company focused on innovative approaches to driving durable behavior change in chronic disease, to positively impact health outcomes and cost of care. Dario creates durable behavior change in chronic conditions. For individuals facing the challenges of diabetes, prediabetes, hypertension, obesity, and other chronic conditions, Dario delivers highly personalized digital interactions, actionable data, engaging digital tools and easy to use monitoring devices plus human support. Combined, these touch points make doing the "right thing the easy thing" by encouraging proactive, positive behavior changes that lead to improved health outcomes. Dario chronic condition digital therapeutics solution and the MyDario™ mobile app is loved and recommended by close to 100,000 users around the globe--with a 4.9 star rating across 11,000 reviews on the Apple App Store, and world-class Net Promoter Score (NPS) of 77.

Using AI, we leverage and harness your knowledge, your experience and the data you input into Quin to surface the information you need at the right time, at a glance. Quin gives you information you can trust because it came from your experience.

Dario recognizes that much of what creates worsening in chronic disease is behavior--the choices people make directly influence short and long-term outcomes. In order to truly improve outcomes in chronic disease, behavior change should not be the hardest thing to do--it should, in fact, be the easiest. Dario empowers members with clinically proven, easy to use tools and approaches that help them recognize, address and change the overlapping behaviors that cause worsening of their conditions. The program includes: Program Focus: Diabetes, hypertension, pre-diabetes, obesity and behavioral conditions impacting chronic disease such as stress, anxiety and loneliness. Dario Devices: Easy to use digital devices that interface directly and simply with the member’s existing smart phone (IOS and Android), and include blood glucose, blood pressure monitors and weight scale MyDario™ App: available to download from the App Store Clinical indications upon data capture (e.g., weight increase/decrease, glucose in-range, blood pressure high/low) Contextual logging of the specific event and all its related data (e.g., location, carbs, food pictures, medication and insulin intake, physical activity, mood, time, notes) Real-time AI driven digital feedback and intervention based on positive/negative trends, cause/effect alerts, and lapse in clinical data capture over time In-app alerts with calls to action and positive messaging Automatic log-book: Records all user activities and presents clear trend graphs over time Dario Journey Engine: Behavior is a predominant driver of chronic disease. DarioHealth's unique approach to changing behavior is powered by its AI-driven Journey Engine. Applying tens of billions of data points from over 65,000 Dario users in combination with an individual's own data and preferences, the platform makes effective behavior change the path of least resistance through a personalized user experience. DarioEngage: A flexible, open platform that enables real-time coaching and support and direct viewing of digital inputs from devices and member. Coaching can be delivered by a Dario coach or a Client/Third Party coach. Dario Engage provides immediate data on member measurements and inputs, allowing for a rich coaching experience and data driven decision making.

Compared to Competitive Offerings Dario: 1. HIGHER RETURN ON INVESTMENT Lower price: Dario is priced 33-50% lower than competitive offerings Pay only for engaged members: Dario charges ONLY for members who are actively engaged in the program and demonstrating regular use. No device fee stacking: Dario does not double or tripling of PEMPM when an employee requires additional devices. 2. FULLY INTEROPERABLE: Dario Offers Open Platform, API, Data Sharing and Flexible Coaching- Data Sharing: Dario’s open platform allows data sharing to client or third-party platform Coaching by client, third party or Dario: DarioEngage web-based platform allows coaching to be driven by client, third party or Dario Interoperability: Dario supports API integration with client or third-party platforms 3. BROAD ADOPTION AND EXPERIENCE, DARIO IS LOVED BY USERS 65,000 users currently pay for Dario out of their own pockets 80% of paying users are still engaged at 12 months 15,000+ users access their MyDario™ application daily Apple App Store: 11,000+ reviews and 4.9 STARS Users Recommend Dario, with a Net Promoter Score (NPS) of 77 4. CLINICALLY VALIDATED: Demonstrates Robust and Validated Clinical and Financial Outcomes 11 published studies demonstrating both efficacy and user durability Study analytics that include 3.4 million Dario user measurements Studies with data from 40,000+ Dario users Durable outcomes measured over two years 50% reduction in hypoglycemic events 60% reduction in hyperglycemic events eHbA1c reduction of 1.4% resulting in projected cost reductions of $2,396 PEMPY